Mon, Jan 26, 2015, 12:07 AM EST - U.S. Markets open in 9 hrs 23 mins

Recent

% | $
Quotes you view appear here for quick access.

CombiMatrix Corporation Message Board

pharmaapproved 266 posts  |  Last Activity: Jan 23, 2015 8:15 AM Member since: Jun 7, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Arena and EnteroMedics
    Google; How investors can play the war against ‘globesity’

  • Efforts to fight the rising rate of global obesity are opening up new opportunities for investors, says a new report. EnteroMedics mentioned in article.

    Google: How investors can play the war against ‘globesity’

  • Reply to

    IMS Rx (Week of 12/05/2014)

    by sharonconk Dec 12, 2014 10:24 AM
    pharmaapproved pharmaapproved Dec 12, 2014 10:36 AM Flag

    This could explain the shortage at pharmacies. Couple high demand with a labeling issues and you can see why shelves may be empty.

  • Reply to

    Recall larger than first thought?

    by pharmaapproved Dec 12, 2014 10:14 AM
    pharmaapproved pharmaapproved Dec 12, 2014 10:31 AM Flag

    I posed it as a question because I don't know if it's true or not. What's poppycock is the pps!

  • Reply to

    Recall larger than first thought?

    by pharmaapproved Dec 12, 2014 10:14 AM
    pharmaapproved pharmaapproved Dec 12, 2014 10:26 AM Flag

    The labeling issue. Is it a larger problem then what was said last week? I'm just telling you what I'm seeing. It should be a short lived event, but as you know it doesn't take much in the way of news to push this stock down.

  • Reply to

    Recall larger than first thought?

    by pharmaapproved Dec 12, 2014 10:14 AM
    pharmaapproved pharmaapproved Dec 12, 2014 10:24 AM Flag

    Not sure if Eisai is paying for it or not. This sounds like an Arena issue.

  • pharmaapproved by pharmaapproved Dec 12, 2014 10:14 AM Flag

    pharmacy's have no stock. Sounds like the recall due to labeling issues may be a little longer lasting than first thought. I don't know how true this is but it is what's making rounds over the net.

  • Reply to

    First-year VBLOC sales

    by bammupyours Dec 11, 2014 2:37 PM
    pharmaapproved pharmaapproved Dec 12, 2014 9:38 AM Flag

    IF approved VBLOC will be the "least invasive" procedure available. Also you mentioned in another post the length of the procedure was 50 to 90 minutes. This is true, but most surgeons don't even enter the room until it's time to start cutting. They can probably do the procedure in 10-20 minutes before being passed off to the recovery staff. It's like a production line.

  • pharmaapproved pharmaapproved Dec 12, 2014 8:13 AM Flag

    I thought he was out at the end of the year anyway. At least that's what one poster has claimed for some time now. But if not someone should make mention of the "shareholder value" Craig said was #1 priority two years ago. I think the pps was sitting around $8 then. Not only that but what about Jack when he's said in the past "as you can imagine we have multiple parties interested." Was all that just bait or are there multiple parties still interested. And if there is still interest what are they interested in? I have no position in the stock just curious in the outcome here. Good luck longs!!!

  • Reply to

    50,000 VBLOC procedures in 18 months

    by adelfig Dec 11, 2014 8:40 AM
    pharmaapproved pharmaapproved Dec 12, 2014 7:38 AM Flag

    Your right I should have used the word "potential" side effects. However the drug interactions are what they are. How many obese patients are going to be taking one or more of the thousands of drugs on the list? The poster I was responding to was making a false claim "in 6 months there will be,on the market,a weight loss pill that is safe, effective and inexpensive" That's just not true!

  • Reply to

    First-year VBLOC sales

    by bammupyours Dec 11, 2014 2:37 PM
    pharmaapproved pharmaapproved Dec 11, 2014 5:23 PM Flag

    1. The AMA has classified obesity as a disease. Next year it will be mandatory for insures to offer one or more plans that cover treatment for obesity
    2. EnteroMedics has already said they have third-party lenders ready for those who are unable to pay out of pocket.
    3. ETRM has already told us they're talking with strategic partners.
    4. ETRM has already told us there is a back-log of patients waiting for approval
    5. Who cares it will be someone else's worry because this company will be SOLD!

  • Reply to

    50,000 VBLOC procedures in 18 months

    by adelfig Dec 11, 2014 8:40 AM
    pharmaapproved pharmaapproved Dec 11, 2014 11:32 AM Flag

    Side Effects of approved drugs:
    Valvular heart disease, Changes in attention or memory, Mental problems, Depression or thoughts of suicide, Painful erections, Headache, dizziness, fatigue, nausea, dry mouth, constipation, Birth defects (cleft lip/cleft palate) insomnia, panic attacks, Serious eye problems, Concentration, memory, and speech difficulties, seizures, Kidney stones, rash, itching, hives, fever, swollen lymph glands, painful sores in your mouth or around your eyes, swelling of your lips or tongue, chest pain, trouble breathing, liver damage, hepatitis and the list goes on
    -------------------------------------------------------------------------------------------------------------
    Drug Interactions:
    OREX Contrave = (Bupropion and Naltrexone)
    365 major drug interactions (1939 brand and generic names)
    358 moderate drug interactions (4404 brand and generic names)
    7 minor drug interactions (19 brand and generic names)
    ---------------------------------------------------------------------------------------------------------------
    ARENA BELVIQ = Novel
    196 major drug interactions (1541 brand and generic names)
    213 moderate drug interactions (1429 brand and generic names)
    3 minor drug interactions (8 brand and generic names)
    ----------------------------------------------------------------------------------------------------------------
    VIVUS Qsymia = (P and Topiramate)
    394 major drug interactions (2758 brand and generic names)
    343 moderate drug interactions (2277 brand and generic names)
    4 minor drug interactions (15 brand and generic names)
    ---------------------------------------------------------------------------------------------------------------
    EnteroMedics VBLOC Maestro = Novel
    0 Major drug interaction
    0 Moderate drug interactions
    0 Minor drug interactions
    Side effects: Heart burn which go away in about a week

  • Reply to

    50,000 VBLOC procedures in 18 months

    by adelfig Dec 11, 2014 8:40 AM
    pharmaapproved pharmaapproved Dec 11, 2014 10:20 AM Flag

    "In 6 months?" What pill will that be?

  • Reply to

    big sell now

    by walteriedel Dec 10, 2014 1:56 PM
    pharmaapproved pharmaapproved Dec 10, 2014 4:09 PM Flag

    Doubt it, but if so ETRM just puts it focus back on the EU & Australia. What;s that worth!? The market's telling us $100M imo considering U.S. approval has not been baked in. And if this is the case it will be a nice change for once. These days company/s pps get ahead of themselves creating a sell the news event. I don't believe that;s happened here.

  • Reply to

    Interesting

    by innsbrooklad Dec 10, 2014 10:43 AM
    pharmaapproved pharmaapproved Dec 10, 2014 11:18 AM Flag

    7,156,670 down from 7,437,455
    Source: Nasdaq

  • Reply to

    Question about FDA filing

    by investtxs Dec 9, 2014 3:25 PM
    pharmaapproved pharmaapproved Dec 9, 2014 6:39 PM Flag

    FDA own words:
    Novel technology addressing unmet medical need in assessing benefit and risk, FDA considers whether a device represents or incorporates breakthrough technologies and addresses an unmet medical need (OBESITY).
    A device may address unmet medical need by providing a clinically meaningful advantage over existing technologies, providing a greater clinically meaningful benefit than existing therapy, (POSING LESS RISK THAN EXISTING THERAPY), or providing a treatment or means of diagnosis where no alternative is available. (THE ALTERNATIVES ARE DANGEROUS PILLS, HAVING YOUR INSIDES ALTERED OR WORSE RIPPED APART)
    It is not unusual for novel devices that address an unmet medical need to have relatively small probable benefits, and FDA may determine the novel device to be reasonably safe and effective even though the applicant demonstrates a relatively small probable benefit. (THE BENEFITS ARE NOT IN QUESTION AS THE VOTE WAS ALMOST UNANIMOUS)
    In addition, the development of innovative technology may provide additional future benefits (DIABETES, CARDIOVASCULAR DISEASE) to patients.
    With subsequent iterations of the device its benefit-risk profile may change (e.g., the benefits may increase or the risks may be reduced), the expected level of safety and effectiveness may change, and later versions may offer significant advantages over the initial device. In these circumstances, in order to facilitate patient access to new devices important for public health and to encourage innovation, we may tolerate greater uncertainty in an assessment of benefit or risk than for most established technologies, particularly when providers and patients have limited alternatives available. (THE TECHNOLOGY IS NEW WHEN IT COMES TO WEIGHT LOSS & WITH APPROVAL ETRM CAN THEN BEGIN WORKING ON A NEXT GENERATION DEVICE)

  • Reply to

    Approval

    by innsbrooklad Dec 7, 2014 11:35 AM
    pharmaapproved pharmaapproved Dec 7, 2014 12:34 PM Flag

    Inns, About "$100MM up front and a double digit royalty." If we can get a deal like that the pps would surge. And like you I would hate to see them get taken out under that scenario. Anyway with approval those of us invested prior to a positive decision should have nothing to worry about as long they stay focused on the future. The possibilities going forward are endless and all favor long-term shareholders who are patient.

    There was an article out of EU last week recommending weight loss surgery over pills. We know there where 20 million people in the U.S. who qualified for surgery here in the U.S. who opted out because procedures offered today are risky. Potential patients want less invasive options like VBLOC. I would imagine the same could be said about the rest of the world!

  • Reply to

    Price target

    by sguceri Dec 6, 2014 5:43 PM
    pharmaapproved pharmaapproved Dec 7, 2014 9:38 AM Flag

    I have no idea who he is. What I do know is he has quite the following. As I said before I think he and most of his followers are short term traders. If anything it "might" give a short term boost to the pps. I'm not interested in short term pops here and am looking forward more to the roll-out and what comes after that! GL

    Here's link to what Sheff put out Friday:
    screencast-o-maticDOTcom/watch/c2lfrue0ZF

  • Reply to

    Price target

    by sguceri Dec 6, 2014 5:43 PM
    pharmaapproved pharmaapproved Dec 6, 2014 7:44 PM Flag

    Mistake I guess. I looked all day Friday for anything about the downgrade and never could find anything about it. Anyway, these analyst don't know anything more than we do at this point. All we know is the FDA is working with ETRM on "finalizing" the label, and once approved there are patients standing in line. ETRM has not disclosed what the initial demand is, but from what I've read we could be "shocked!" We'll see!!!
    FYI: Sheff put out another plug to his 4000+ followers

  • Reply to

    New 8K

    by den1man Dec 5, 2014 5:36 PM
    pharmaapproved pharmaapproved Dec 5, 2014 6:11 PM Flag

    Esiai & Arena just can't get out of each others way. Eisai has done nothing but fumble the ball since launch. First it was with over exaggerated first year projections. Then it was vouchers which where out of date. Then it was poorly done commercials. EU and now Canada on hold and will need to go though the whole process all over again. When does it end for this company!? You longs can't tell me your happy with this investment over the past two years. Maybe I shouldn't even be posting here anymore, but being I have followed Arena for several years I am interested in the outcome. GL longs!!!!

CBMX
1.77+0.0900(+5.36%)Jan 23 3:59 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.